Lionco Pharmaceutical Group Co (SHSE:603669) Piotroski F-Score: 5 (As of Jul. 05, 2026) — Near Median


SHSE:603669 Lionco Pharmaceutical Group Co Ltd SHSE:603669
46 GF Score
Price ¥6.12
GF Value ¥6.81
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Lionco Pharmaceutical Group Co Piotroski F-Score?

Lionco Pharmaceutical Group Co SHSE:603669 +0.99% 46 Piotroski F-Score is 5 as of Jul. 05, 2026, which is at its 10-year median of 5.00. GuruFocus rates SHSE:603669 with a GF Score™ of 46/100 and a GF Value™ of ¥6.81 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, Lionco Pharmaceutical Group Co ranks better than 61.39% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lionco Pharmaceutical Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Lionco Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:603669' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Lionco Pharmaceutical Group Co was 8. The lowest was 1. And the median was 5.

Lionco Pharmaceutical Group Co  (SHSE:603669) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Lionco Pharmaceutical Group Co Piotroski F-Score Related Terms


Lionco Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Lionco Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lionco Pharmaceutical Group Co Piotroski F-Score Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 2.00 5.00 4.00

Lionco Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 4.00 5.00

SHSE:603669 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lionco Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lionco Pharmaceutical Group Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lionco Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Lionco Pharmaceutical Group Co's Piotroski F-Score falls into.


SHSE:603669
46GF Score
Lionco Pharmaceutical Group Co Ltd SHSE:603669
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -17.112 + 1.231 + -158.736 + 2.956 = ¥-171.7 Mil.
Cash Flow from Operations was -25.39 + -79.093 + -14.812 + -29.234 = ¥-148.5 Mil.
Revenue was 121.486 + 110.253 + 40.623 + 86.536 = ¥358.9 Mil.
Gross Profit was 16.635 + 93.119 + 17.167 + 24.962 = ¥151.9 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1231.431 + 1210.091 + 1201.23 + 1106.779 + 1121.672) / 5 = ¥1174.2406 Mil.
Total Assets at the begining of this year (Mar25) was ¥1,231.4 Mil.
Long-Term Debt & Capital Lease Obligation was ¥20.1 Mil.
Total Current Assets was ¥542.0 Mil.
Total Current Liabilities was ¥472.6 Mil.
Net Income was -24.359 + -6.49 + -83.874 + -18.621 = ¥-133.3 Mil.

Revenue was 64.616 + 89.553 + 148.75 + 50.121 = ¥353.0 Mil.
Gross Profit was 19.906 + 35.722 + 78.563 + 14.048 = ¥148.2 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1483.165 + 1448.073 + 1205.652 + 1255.334 + 1231.431) / 5 = ¥1324.731 Mil.
Total Assets at the begining of last year (Mar24) was ¥1,483.2 Mil.
Long-Term Debt & Capital Lease Obligation was ¥267.1 Mil.
Total Current Assets was ¥574.7 Mil.
Total Current Liabilities was ¥209.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lionco Pharmaceutical Group Co's current Net Income (TTM) was -171.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lionco Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was -148.5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-171.661/1231.431
=-0.13939961

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-133.344/1483.165
=-0.08990503

Lionco Pharmaceutical Group Co's return on assets of this year was -0.13939961. Lionco Pharmaceutical Group Co's return on assets of last year was -0.08990503. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Lionco Pharmaceutical Group Co's current Net Income (TTM) was -171.7. Lionco Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was -148.5. ==> -148.5 > -171.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=20.131/1174.2406
=0.01714385

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=267.069/1324.731
=0.20160244

Lionco Pharmaceutical Group Co's gearing of this year was 0.01714385. Lionco Pharmaceutical Group Co's gearing of last year was 0.20160244. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=541.976/472.575
=1.14685711

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=574.661/209.21
=2.74681421

Lionco Pharmaceutical Group Co's current ratio of this year was 1.14685711. Lionco Pharmaceutical Group Co's current ratio of last year was 2.74681421. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Lionco Pharmaceutical Group Co's number of shares in issue this year was 720.953. Lionco Pharmaceutical Group Co's number of shares in issue last year was 721.754. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=151.883/358.898
=0.42319266

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=148.239/353.04
=0.41989293

Lionco Pharmaceutical Group Co's gross margin of this year was 0.42319266. Lionco Pharmaceutical Group Co's gross margin of last year was 0.41989293. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=358.898/1231.431
=0.29144792

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=353.04/1483.165
=0.23803151

Lionco Pharmaceutical Group Co's asset turnover of this year was 0.29144792. Lionco Pharmaceutical Group Co's asset turnover of last year was 0.23803151. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lionco Pharmaceutical Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Lionco Pharmaceutical Group Co (SHSE:603669) has a Piotroski F-Score of 5 as of Jul. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lionco Pharmaceutical Group Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Lionco Pharmaceutical Group Co's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Lionco Pharmaceutical Group Co ranks #378 out of 979 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Lionco Pharmaceutical Group Co's Piotroski F-Score too high?
Lionco Pharmaceutical Group Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Lionco Pharmaceutical Group Co's value of 5 is 0% at this industry median. Based on the distribution chart, Lionco Pharmaceutical Group Co ranks #378 out of 979 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lionco Pharmaceutical Group Co has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lionco Pharmaceutical Group Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lionco Pharmaceutical Group Co ranks #378 out of 979 companies for Piotroski F-Score. This puts Lionco Pharmaceutical Group Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Lionco Pharmaceutical Group Co's value of 5 is 0% at this benchmark. Historically, Lionco Pharmaceutical Group Co's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Lionco Pharmaceutical Group Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lionco Pharmaceutical Group Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lionco Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lionco Pharmaceutical Group Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lionco Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co (SHSE:603669) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.81, compared to a current price of ¥6.12 — trading 10.1% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Lionco Pharmaceutical Group Co's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Lionco Pharmaceutical Group Co (SHSE:603669), the current Piotroski F-Score is 5 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lionco Pharmaceutical Group Co (SHSE:603669) Overvalued in 2026?

Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥6.12 is trading 10.1% below its estimated GF Value™ of ¥6.81. GuruFocus considers Lionco Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603669:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ¥6.81 vs. price of ¥6.12 (10.1% below fair value)
  • GF Score™: 46/100 with 6 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#378 of 979)

No single metric tells the full story. See the SHSE:603669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lionco Pharmaceutical Group Co Business Description

Address No. 20, National Highway 349, Naidong District, Shannan, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
46GF Score

Get the complete analysis for SHSE:603669

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.12
Price
¥6.81
GF Value